What is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)?

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rarely diagnosed fatal heart disease affecting an estimated 400,000 people globally, although the true prevalence is unknown and may be higher. Bayer is committed to optimize the care for patients living with this progressive disease, to prolong lives, and improve patients’ quality of life.